GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases. Its stock price is highly volatile, driven by news about the progress of clinical trials in one of the most complex areas of medicine.
Share prices of companies in the market segment - Neuro
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease and atrophy by targeting protein clusters in the brain. We've classified it in the "Neuro" segment. The chart below shows the overall dynamics of this complex but crucial pharmaceutical sector.
Broad Market Index - GURU.Markets
Alterity Therapeutics is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's disease. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Alterity compares to it.
Change in the price of a company, segment, and market as a whole per day
ATHE - Daily change in the company's share price Alterity Therapeutics
For Alterity Therapeutics, which develops drugs for neurodegenerative diseases, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Neuro
Alterity Therapeutics Limited is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ATHE, which focuses on neurodegenerative diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its shares react to research data. This scientific research, full of risks and hopes, creates a volatile rhythm that feeds into the overall pulse of the global stock market on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alterity Therapeutics
Alterity Therapeutics' year-to-date performance is a story of developing a new approach to treating neurodegenerative diseases. Its 12-month market cap is entirely dependent on clinical trial data for its drug, which targets protein aggregation in Parkinson's disease. Success could lead to a breakthrough in this highly complex area of medicine.
Annual dynamics of market capitalization of the market segment - Neuro
Alterity Therapeutics Limited is an Australian biotech company developing drugs for the treatment of neurodegenerative diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alterity Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs for the treatment of neurodegenerative diseases. Its monthly performance is entirely dependent on progress in its clinical trials. News of its lead candidate's clinical trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Neuro
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach is based on targeting iron accumulation in the brain. The neuroscience segment of the pharmaceutical market reflects the high risks and expectations associated with drug discovery for these devastating conditions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its shares move with scientific news rather than with the market. The price reflects investor expectations regarding the success of clinical trials, making its performance independent and volatile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alterity Therapeutics
Alterity Therapeutics, an Australian biotech developing drugs to treat neurodegenerative diseases, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials, reflecting the risks and hopes in the fight against Parkinson's and Alzheimer's diseases.
Weekly dynamics of market capitalization of the market segment - Neuro
Alterity Therapeutics develops drugs to treat neurodegenerative diseases such as Parkinson's. This chart compares its volatile, news-driven performance with general trends in neuroscience to understand how much investors believe in its scientific approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alterity Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that ATHE's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
ATHE - Market capitalization of the company Alterity Therapeutics
The Alterity Therapeutics chart is a financial map of the fight against neurodegenerative diseases. This Australian company's market cap reflects the hopes for its drugs targeting protein misfolding in Parkinson's and Alzheimer's diseases. Its dynamics are a barometer of progress in clinical trials of this innovative strategy.
ATHE - Share of the company's market capitalization Alterity Therapeutics within the market segment - Neuro
Alterity Therapeutics' stake in the neuroscience sector is a bet on a new approach to treating neurodegenerative diseases such as Parkinson's. The company develops drugs that target protein aggregation in the brain. Its market share reflects the potential of this innovative approach.
Market capitalization of the market segment - Neuro
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. The chart below shows the overall market capitalization of this complex sector. Its dynamics reflect both the enormous promise and the risks.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its market capitalization reflects a bet on a new treatment approach. The chart below shows the weightings of companies battling these diseases.
Book value capitalization of the company, segment and market as a whole
ATHE - Book value capitalization of the company Alterity Therapeutics
For Alterity Therapeutics, book value represents its R&D capital. The chart below shows its financial resources for developing drugs for neurodegenerative diseases. This level is an indicator of its ability to fund its research programs in Australia and the US.
ATHE - Share of the company's book capitalization Alterity Therapeutics within the market segment - Neuro
Alterity Therapeutics is a biotech company developing treatments for neurodegenerative diseases. Its core capital is intellectual property. The share of physical assets chart will reflect its research-focused model, where patents are its primary assets.
Market segment balance sheet capitalization - Neuro
Alterity Therapeutics is a biotech company whose value is created in laboratories developing drugs for neurodegenerative diseases. It's a "light" model, based on science. The chart below illustrates the extent to which the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Alterity Therapeutics' assets represent capital invested in developing drugs to treat neurodegenerative diseases, such as Parkinson's, by targeting misfolded protein clusters. The book value chart shows the resources devoted to this breakthrough scientific hypothesis.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alterity Therapeutics
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its market capitalization reflects its scientific approach. The chart illustrates the risks and hopes associated with finding cures for these complex diseases.
Market to book capitalization ratio in a market segment - Neuro
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its value is its science. The chart shows the premium investors are paying for the potential of its developments.
Market to book capitalization ratio for the market as a whole
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart shows how the market values the science behind the treatment of incurable diseases. The company's market capitalization is a bet on the success of its clinical trials, a high-risk proposition.
Debts of the company, segment and market as a whole
ATHE - Company debts Alterity Therapeutics
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart shows how the company is raising capital to fund its lengthy and complex clinical trials in this challenging area of medicine.
Market segment debts - Neuro
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Their approach is aimed at restoring metal balance in the brain. The chart shows the general biotech sector norms against which Alterity is raising capital to test its unique scientific hypothesis in clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. This cutting-edge science requires lengthy and expensive research. This chart shows the company's reliance on debt to fund its R&D, which is a direct indicator of its financial risk.
Market segment debt to market segment book capitalization - Neuro
Developing drugs to treat neurodegenerative diseases like Parkinson's, like Alterity's, is a long and risky journey. This chart shows how the biotech sector funds its research. It allows one to understand Alterity Therapeutics' financial model and its reliance on external capital to advance its molecules through clinical trials.
Debt to book value of all companies in the market
Alterity Therapeutics fights neurodegenerative diseases such as Parkinson's. Biotech research in this field requires massive, long-term investments. The chart shows how their debt burden, required for R&D, compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Alterity Therapeutics
This chart shows the valuation of Alterity Therapeutics, a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its value is determined not by current profits, but by the potential of its scientific approach to combating the accumulation of "abnormal" proteins in the brain.
P/E of the market segment - Neuro
This indicator represents the average valuation for the biotech sector in which Alterity Therapeutics operates. It reflects the overall level of hope and risk in the field of neurodegenerative disease treatment. The chart serves as a barometer of investor sentiment for the entire development segment in this complex field.
P/E of the market as a whole
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. It focuses on restoring metal balance in the brain. This chart shows biotech sentiment. It helps understand how the market views this innovative, yet unproven, approach in a highly complex therapeutic area.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease and atypical parkinsonism. Its approach is based on the redistribution of excess iron in the brain. Its future depends on clinical success. This chart reflects investor expectations for its unique scientific approach to these complex diseases.
%20P%2FE%20Alterity%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alterity-Therapeutics&v=1772665139139 "Chart of the company's future (projected) P/E Alterity Therapeutics")
Future (projected) P/E of the market segment - Neuro
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its approach is based on targeting the accumulation of abnormal proteins in the brain. This chart reflects expectations for the biotech sector, helping to assess how the market views this scientific strategy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772665139166 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Their approach targets iron redistribution in the brain. This graph of overall expectations demonstrates the market's willingness to fund innovative approaches in medicine. Investor optimism is essential to support such long-term and risky research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772665139210 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart shows the cost of innovative research. Future profits depend on the success of clinical trials of its compounds aimed at restoring metal balance in the brain.
Profit of companies in the market segment - Neuro
Rein Therapeutics Inc., formerly Aileron, is a clinical-stage biotech company. Its financial position is typical for the industry: focused on science rather than profit. This chart illustrates how the sector as a whole operates on venture capital, where years of losses are reinvested in the pursuit of the next breakthrough drug that could generate billions.
Overall market profit
Alterity Therapeutics is a biotechnology company developing drugs for the treatment of neurodegenerative diseases such as Parkinson's disease. The company is focusing on a new approach targeting the aggregation of the alpha-synuclein protein. Its success depends on the results of clinical trials in this complex area of medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alterity Therapeutics
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its profit outlook is long-term and depends on the success of clinical trials. This chart reflects analyst expectations for its scientific approach to treating these complex diseases.
%20profit%20of%20the%20company%20Alterity%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alterity-Therapeutics&v=1772665139335 "Graph of future (projected) profit of the company Alterity Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach aims to redistribute excess iron in the brain. This chart shows profitability forecasts for the neuroscience sector, reflecting the potential of new approaches to treating complex brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772665139419 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its future depends on success in clinical trials. This earnings forecast chart is important for assessing the overall investment climate and the market's willingness to finance long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772665139435 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach involves targeting clusters of misfolded proteins in the brain. The chart reflects investor sentiment on its scientific hypothesis, which could lead to the development of a revolutionary treatment.
P/S market segment - Neuro
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its approach targets protein aggregation in the brain. This chart shows the average valuation for the sector, allowing one to gauge the market's perception of the potential of Alterity's science.
P/S of the market as a whole
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its approach is based on the redistribution of excess metal ions in the brain. This chart, reflecting the average estimated real income, clearly highlights how biotech investments are a bet on scientific breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alterity Therapeutics
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart reflects investor confidence in the future success of its scientific approach. The valuation is based on expectations for clinical trials, which could lead to the development of a new class of drugs.
%20P%2FS%20Alterity%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alterity-Therapeutics&v=1772665139632 "The graph of the company's future (projected) P/S Alterity Therapeutics")
Future (projected) P/S of the market segment - Neuro
Alterity Therapeutics is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's disease and atypical parkinsonism. Its approach is based on the redistribution of excess iron in the brain. The chart shows how investors estimate Alterity's future sales, reflecting the potential of its innovative therapy.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772665139635 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This graph reflects the hopes associated with the treatment of neurodegenerative diseases such as Parkinson's. Alterity Therapeutics is developing drugs that target excess iron in the brain, which is believed to be a contributing factor to the disease. Their scientific approach inspires confidence that new ways to combat these devastating conditions will be found.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772665139660 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, such as Parkinson's disease. Currently, the company has no commercial sales revenue. Its financial chart reflects investments in clinical trials and research.
Sales of companies in the market segment - Neuro
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach involves redistributing excess iron in the brain. This chart shows total revenue in the neuroscience pharmaceutical segment. It illustrates the company's search for new therapeutic targets to combat complex diseases.
Overall market sales
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach is based on the redistribution of excess metal ions in the brain. Success depends on clinical data. This overall economic climate affects the availability of funding for innovative approaches to treating brain diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach is based on the redistribution of excess iron in the brain. The future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, which are bets on a new treatment method.
%20sales%20of%20the%20company%20Alterity%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alterity-Therapeutics&v=1772665139830 "Schedule of future (projected) sales of the company Alterity Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its approach involves targeting clusters of misfolded proteins. This chart displays forecasts for the entire neuroscience pharmaceutical segment, showing analysts' overall expectations for this area.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772665139851 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. The company is in the clinical stage, and its future depends on the success of its trials. This overall economic activity schedule impacts the availability of capital to fund long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772665139864 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This metric is a financial reflection of its scientific mission, demonstrating the amount of investment in clinical trials required to bring a new generation of drugs to market.
Market segment marginality - Neuro
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Profitability is a long-term goal. This metric reflects its operational structure and the level of investment in its unique scientific approach to treating these complex diseases.
Market marginality as a whole
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as Parkinson's disease. Their approach is aimed at redistributing iron in the brain. Their success depends on clinical data. This gross margin schedule does not affect their research activities.
Employees in the company, segment and market as a whole
Number of employees in the company Alterity Therapeutics
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. While in the clinical stage, it has a small staff. This chart shows the dynamics of the team of scientists leading research in one of the most complex and time-consuming areas of medicine.
Share of the company's employees Alterity Therapeutics within the market segment - Neuro
Alterity Therapeutics develops drugs to treat neurodegenerative diseases such as Parkinson's. This chart shows the percentage of neuroscientists specializing in protein misfolding that the company employs. Its team is working to address one of the fundamental causes of neuronal death.
Number of employees in the market segment - Neuro
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart shows overall employment in the neuroscience sector. It illustrates how the company is targeting the accumulation of misfolded proteins in the brain, which is believed to be a cause of these diseases.
Number of employees in the market as a whole
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases like Parkinson's by targeting protein aggregation in the brain. This total employment chart reflects the contribution of the research-intensive sector, where companies like Alterity are attracting the best minds to combat some of humanity's most complex diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alterity Therapeutics (ATHE)
Alterity Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart is a classic example of biotech. The high market capitalization per employee suggests that the market is not evaluating current operations, but rather the potential of unique developments created by a small scientific team.
%20of%20the%20company%20Alterity%20Therapeutics%20(ATHE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alterity-Therapeutics-ATHE&v=1772665140306 "Chart of market capitalization per employee (in thousands of dollars) of the company Alterity Therapeutics (ATHE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. Their valuation is based on the potential of their research. This metric reflects the enormous value the market places on their research. A high valuation reflects investors' hopes for a breakthrough in the treatment of these devastating conditions.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772665140327 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. Its valuation is dependent on the success of clinical trials. This metric reflects how investors value the company's scientific approach to complex diseases with a huge potential market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772665140337 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alterity Therapeutics (ATHE)
Alterity Therapeutics (ATHE) is a clinical-stage biotech R&D company developing drugs for the treatment of neurodegenerative diseases such as Parkinson's. This is pure science. This metric demonstrates their capital burn rate—the net loss (R&D expenses) per scientist.
%20Chart%20Alterity%20Therapeutics%20(ATHE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alterity-Therapeutics-ATHE&v=1772665140346 "Company Profit Per Employee (in thousands of dollars) Chart Alterity Therapeutics (ATHE)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Alterity Therapeutics is a clinical-stage biotech focused on treating neurodegenerative diseases. As with other R&D firms, this timeline is a goal for the future. Currently, all the value is concentrated in their scientific team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772665140349 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Alterity Therapeutics (ATHE) is a biotech company developing drugs for the treatment of neurodegenerative diseases, such as Parkinson's disease. They are in the clinical stage. This chart shows that their current business is R&D expenses. Their profit per employee is negative.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772665140360 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alterity Therapeutics (ATHE)
For Alterity Therapeutics, a company developing drugs to treat neurodegenerative diseases such as Parkinson's, this graph reflects the clinical trial stage. Future revenue growth per employee depends on the success of its innovative treatment approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alterity-Therapeutics-ATHE&v=1772665140374 "Sales chart per company employee Alterity Therapeutics (ATHE)")
Sales per employee in the market segment - Neuro
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This is R&D. This metric reflects the average revenue per employee for the segment. It demonstrates how productive their research team is in this highly complex field compared to other biotech companies.
Sales per employee for the market as a whole
Alterity Therapeutics (ATHE) is an Australian clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases (Parkinson's disease). Currently, its staff consists entirely of researchers. This metric is critical for ATHE: it is at zero. Its future growth will signal the success of their R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Alterity Therapeutics (ATHE)
Alterity Therapeutics is an Australian biotech company trying to treat neurodegenerative diseases like Parkinson's. This is one of the most challenging areas in medicine. This chart shows how many investors are betting that its scientific approach will fail in clinical trials, which is almost the norm for this category of diseases.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alterity-Therapeutics-ATHE&v=1772665140420 "Short Shares Chart for the Company Alterity Therapeutics (ATHE)")
Shares shorted by market segment - Neuro
Alterity Therapeutics (ATHE) is an Australian biopharmaceutical company developing drugs to treat neurodegenerative diseases (such as Parkinson's) by targeting iron imbalances. This chart shows the overall short position in the neuroscience biotech sector, reflecting the overwhelming skepticism surrounding their new therapeutic target.
Shares shorted by the overall market
Alterity Therapeutics is a biotech company working on complex neurodegenerative diseases (such as Parkinson's). This chart illustrates the overall market "fear." For companies whose research will take years, such pessimism is fatal: investors are unwilling to wait, and raising new capital for R&D becomes nearly impossible.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alterity Therapeutics (ATHE)
This chart for Alterity Therapeutics is a clear barometer of hope in biotech. The company targets neurodegenerative diseases such as Parkinson's. Any positive clinical trial data, even early ones, triggers a flurry of buying and "overheating" (above 70). Meanwhile, the slightest delay or hint of side effects leads to sharp sell-offs, sending the oscillator into "oversold" territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alterity-Therapeutics-ATHE&v=1772665140462 "RSI 14 indicator chart for the company's stock Alterity Therapeutics (ATHE)")
RSI 14 Market Segment - Neuro
Alterity (ATHE) is a "biotech" (Australia), a "brain hunter." They develop drugs to treat neurodegenerative diseases (Parkinson's, atrophy). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ATHE's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Alterity (ATHE) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATHE (Alterity Therapeutics)
Alterity Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases (such as Parkinson's disease). Its approach is to attack iron accumulation in the brain. This chart shows the speculative average price target from analysts based on their belief in this scientific R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATHE-Alterity-Therapeutics&v=1772665140516 "A chart showing analyst consensus forecasts for the expected stock price. ATHE (Alterity Therapeutics)")
The difference between the consensus estimate and the actual stock price ATHE (Alterity Therapeutics)
Alterity (ATHE) is an Australian biotech company developing therapies for neurodegenerative diseases (Parkinson's). This chart is a barometer of their R&D. It measures the vast gap between the speculative price and the consensus target, reflecting the enormous (but risky) potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATHE-Alterity-Therapeutics&v=1772665140522 "A chart showing the difference between the consensus forecast and the actual stock price. ATHE (Alterity Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Alterity Therapeutics is an Australian biotech company developing drugs to treat neurodegenerative diseases (such as Parkinson's) by targeting abnormal brain hardware. This chart shows general expectations for the neuroscience sector, reflecting experts' confidence in this innovative R&D approach.
Analysts' consensus forecast for the overall market share price
Alterity Therapeutics is an Australian biotech company specializing in developing drugs to treat neurodegenerative diseases (Parkinson's) by targeting abnormal iron in the brain. This chart shows overall risk appetite. For Alterity, working in the most complex area of medicine, overall market optimism is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alterity Therapeutics
Alterity is an Australian biotech company attempting to treat Alzheimer's disease (neurodegeneration) by targeting abnormal iron in the brain. Their drug (ATH434) is a chelator that binds and removes excess iron. This chart is a pure indicator of their R&D. It doesn't reflect revenue, but rather a speculative assessment of their scientific approach and clinical trial data.
AKIMA Market Segment Index - Neuro
Alterity Therapeutics (ATHE) is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease, by targeting iron accumulation in the brain. The chart shows the average index for the segment, allowing investors to balance Alterity's innovative approach with the high risk inherent in the neuroscience sector.
The AKIM Index for the overall market
Alterity Therapeutics is an Australian biotech company developing treatments for neurodegenerative diseases (Parkinson's, MSA). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative early-stage scientific story compares to overall economic trends and interest in neuroscience.
